(Q45419055)

English

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection

scientific article published on 9 March 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

0 references

Jonathan L. Heeney

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Norman L. Letvin

7

object named as

Norman L Letvin

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Rong Xu

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Indresh K Srivastava

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Larene Kuller

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Irina Zarkikh

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Zane Kraft

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Zahra Fagrouch

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Susan W Barnett

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Leonidas Stamatatos

10

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

9 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

349

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

276-289

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

AIDS vaccine models: challenging challenge viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Functional impairment of simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

based on heuristic

inferred from DOI database lookup

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

based on heuristic

inferred from DOI database lookup

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

based on heuristic

inferred from DOI database lookup

A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.043

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2006.01.043

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45419055&oldid=2076892769"